Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Advanced Therapies 2021 View overview page

2:21
An update on the UK Cell and Gene Therapy Catapult
Matthew Durdy • 6 Oct 2021
2:07
Addressing remaining barriers to the commercialization of ATMPs
Matthew Durdy • 6 Oct 2021
1:44
The evolving landscape of autologous and allogeneic therapies
Matthew Durdy • 6 Oct 2021
1:17
Moving forward in the CGT field using lessons from the pandemic
Manuel Carrondo • 6 Oct 2021
2:32
The ISCT’s ongoing battle against unproven cell & gene therapies
Miguel Forte • 5 Oct 2021
3:50
Immunogenicity of AAV-based gene therapies
Paul Gissen • 6 Oct 2021
2:54
Enhancing communication in the advanced therapies sector
Neil Hunter • 6 Oct 2021
3:05
The evolving landscape of scientific communication in advanced therapies
Neil Hunter • 6 Oct 2021
2:29
Rekindling communication in the sector following the pandemic
Neil Hunter • 6 Oct 2021
1:49
Collaboration in the cell & gene therapy industry
Neil Hunter • 6 Oct 2021
2:05
Novel technologies for the digitization of the advanced therapy supply chain
Kwok Pang • 6 Oct 2021
1:12
Simplifying analytical testing to drive POC manufacture
Kwok Pang • 6 Oct 2021
2:07
Strategies to facilitate point-of-care manufacture
Kwok Pang • 6 Oct 2021
2:52
Developing manufacturing systems for cell and gene therapies
Kwok Pang • 6 Oct 2021
1:39
Integrating electronic software solutions into healthcare systems
Kwok Pang • 6 Oct 2021
1:44
What can the advanced therapies industry learn from the COVID-19 pandemic?
Matthew Durdy • 6 Oct 2021
The content of VJRegenMed is intended for healthcare professionals